Flotation

Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.

UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.

The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.